

43. Mitteilungsblatt

Nr. 56

Mitteilungsblatt der Medizinischen Universität Wien
Studienjahr 2022/2023
43. Stück; Nr. 56

Bevollmächtigungen

56. Bevollmächtigungen gem. § 27 Abs. 2 UG

56. Bevollmächtigungen gem. § 27 Abs. 2 UG

Gemäß § 27 Abs. 2 UG werden folgende Bevollmächtigungen erteilt:

Auftragsnummer	Projekttitle	Organisationseinheit	Projektleiter (in)
FA731B0212	Neoadjuvant Chemoradiotherapy with sequential Ipilimumab and Nivolumab in RECTal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial	Allgemeinchirurgie_731	Längle Johannes
FA731B0213	Tumor explant cultures to test immuno-oncological drugs (BI compounds) alone and in combinations with other anti-tumor drugs or treatments	Allgemeinchirurgie_731	Bergmann Michael
FA731B0213	Tumor explant cultures to test immuno-oncological drugs (BI compounds) alone and in combinations with other anti-tumor drugs or treatments	Allgemeinchirurgie_731	Bergmann Michael
FA731B2103	Zulassungsstudie für eine MP bei chronischer Stuhlinkontinenz	Allgemeinchirurgie_731	Riss Stefan
FA731B2201	Efficacy of NHS-PEG coated collagen patch (Hemopatch) for prevention of bile leaks after liver resection - a power analysis.	Allgemeinchirurgie_731	Schwarz Christoph
FA731B2305	A Phase III, randomized, open-label, multicenter study, evaluating the efficacy and safety of adjuvant Giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor positive, Her2-negative early breast cancer	Allgemeinchirurgie_731	Fitzal Florian
FA731X0101	TOPMOST	Allgemeinchirurgie_731	Stremitzer Stefan

FA731X0201	An oncolytic influenza A virus adapted to primary organotypic cultures of a CRC patient cohort via directed evolution	Allgemeinchirurgie_731	Kabiljo Julijan
FA738A0807	ICU4Covid - Number101016000	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A0809	European Health Data and Evidence Network	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A1303	Klinischen Prüfung der pharmakologische Sicherheit und Wirksamkeit des Prüfpräparates AP301 powder for reconstitution for solution for inhalation in Patienten mit pulmonalem Permeabilitätsödem bei Patienten mit mäßigem bis schwerem akutem Atemnotsyndrom (ARDS)	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Krenn Katharina
FA738A1602	Treatment of anemia with intravenous iron in patients listed for orthotopic liver transplantation	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Baron David
FA738A2702	A Post-Marked Clinical Follow up Study to evaluate BD Pure Hub Disinfecting Cap use on needle-free connectors	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Windpassinger Marita
FA738C0703	Argatroban Monitoring in kritisch kranken Patienten: Evaluierung eines neuen Ecarin basierten Bedside-Test	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Steinlechner Barbara
FA738A0814	Evaluation of a licensed double-sensor-heat-flux (DHF) non-invasive core temperature sensor in small children and toddlers undergoing surgery	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A0815	Digital skills for Healthcare Transformation	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver

FA738A1902	Implementation of a remote general ward monitoring workflow for high-risk surgical patients after discharge from the ICU: A Non-Comparative Prospective Pilot Study with A Historical Control.	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Willschke Harald
FA611A0105	Integrated virtual and traditional anatomy - Exzellenz in der grenzüberschreitenden medizinischen Ausbildung"	Anatomie und Zellbiologie_310	Weninger Wolfgang
FA611A0301	Henryk Kadyi and the Anatomical departments of the Universities of Vienna, Cracow, Prague and Lviv - A case study in shared European scientific networks	Anatomie und Zellbiologie_310	Bauer Sophia
FA613A0901	The epigenetics of the spermatozoa of HIV-I infected men	Anatomie und Zellbiologie_310	Wossidlo Mark
FA613A0902	EU HORIZON Demystifying the impact of HIV-antiretroviral therapy on fertility and the epigenome of gametes and early embryos	Anatomie und Zellbiologie_310	Wossidlo Mark
FA613A1001	Click-aktivierbare Oligonukleotide für bioorthogonale Translation	Anatomie und Zellbiologie_310	Goldeck Marion
FW613A0101	FWF Preserving Immunological Memory of Previous Generations	Anatomie und Zellbiologie_310	Schäfer Matthias
FA746A0275	A one-year, single-arm, open-label, multicenter study assessing the anatomic outcomes of brolocizumab assessed by OCT-A in adult patients with neovascular age related macular degeneration	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0286	Retinomics for precision profiling of coronary heart disease risk	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula

FA746A0287	A Phase 1 Study to Investigate the Safety, Tolerability, Bioactivity and Pharmacokinetics of Multiple Intravitreal Administrations of KSI-501 in Participants with Macular Edema	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0802	VEREINBARUNG FÜR ALLGEMEINE UNTERSTÜTZUNG IN FORSCHUNG UND LEHRE	Augenheilkunde und Optometrie_746	Abela-Formanek Claudette
FA746A1505	A multicenter, open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with diabetic macular edema (RHONE-X)	Augenheilkunde und Optometrie_746	Pollreisz Andreas
FA746A1507	Deep Learning with Human Foveal Connectome	Augenheilkunde und Optometrie_746	Pollreisz Andreas
FA746A1508	Funded Non-Interventional Study with Primary Data Collection Agreement with an Academic Institution - including a studied ROCHE Product	Augenheilkunde und Optometrie_746	Pollreisz Andreas
FA746A1631	A 64-week, two-arm, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of brolocizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1642	Unrestricted Grant - Untersuchung der funktionellen und morphologischen Langzeit-Auswirkungen der Chorioretinopathia centralis serosa (CCS) über einen Zeitraum von 10 Jahren	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1647	The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresectable Locally Advanced Melanoma	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan

FA746A1648	A phase 3 randomized, double-blind study of ivalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2)	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1649	A phase III, open-label, randomized study to assess the efficacy and safety of extended therapy with Camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or tamoxifen) in patients with ER+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed definitive locoregional therapy and at least 2 years of adjuvant endocrine-based therapy without disease recurrence	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A2007	General Research Funding André	Augenheilkunde und Optometrie_746	Stifter Eva
FA746A2504	Central reading of imaging material in a 52 weeks double blind, randomized and placebo controlled trial evaluating the effect of oral KIN001 150 mg plus pioglitazone 10 mg daily on injection frequency of Standard of Care (SOC) in patients with diagnosed unilateral wet AMD undergoing a treat and extend regimen	Augenheilkunde und Optometrie_746	Gerendas Bianca
FA746A2609	A phase 3, randomized, international multicenter trial of day101 monotherapy versus standard of care chemotherapy in patients with pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A3305	A phase III, multicenter, randomized, double-masked, sham-controlled study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of RO7200220	Augenheilkunde und Optometrie_746	Funk Marion

	administered intravitreally in patients with uveitic macular edema		
FA746A3601	Annotation Service Agreement	Augenheilkunde und Optometrie_746	Reiter Gregor Sebastian
FA746A3801	PRA/JANSSEN Retrospektive Studie zur Dokumentation und Beschreibung der krankheitsbezogenen klinischen, individuellen und soziodemografischen Merkmale von Patienten mit X-chromosomaler Retinitis pigmentosa (XLRP) und der Auswirkungen von XLRP auf Patienten und deren Betreuungspersonen durch Überprüfung von Krankenakten in Kombination mit Querschnittsbefragungen von Patienten und Betreuungspersonen	Augenheilkunde und Optometrie_746	Ritter Markus
FA746A3802	Global Patient Registry of Inherited Retinal Diseases	Augenheilkunde und Optometrie_746	Ritter Markus
FA746A3901	STAR-LIFE: A POST-MARKET REGISTRY ON MINJECT	Augenheilkunde und Optometrie_746	Resch Hemma
FA746A4001	Ocular Findings in Patients Treated with Belantamab Mafodotin – a prospective study focusing on corneal nerves	Augenheilkunde und Optometrie_746	Aschauer Julia
FA746A4101	A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults	Augenheilkunde und Optometrie_746	Reumüller Adrian
FA662A0316	Pilotstudy to evaluate hemocompatibility and cell migration of acellular human extracellular matrix vascular grafts	Biomedizinische Forschung und Translationale Chirurgie_308	Bergmeister Helga

FA662A0317	EU HORIZON Blood as energy source to power smart cardiac devices	Biomedizinische Forschung und Translationale Chirurgie_308	Bergmeister Helga
FA662A0702	Untersuchungen von Biopolymeren im HET-CAM Assay	Biomedizinische Forschung und Translationale Chirurgie_308	Kapeller Barbara
FA662A0901	RNA-LPX therapy for myocardial infarction / MI Drug Candidate	Biomedizinische Forschung und Translationale Chirurgie_308	Kiss Attila
FA662A1001	Repurposing antianginal drugs for immunomodulation in Typ 1 Diabetes	Biomedizinische Forschung und Translationale Chirurgie_308	Hohensinner Philipp
FA654A0101	Implementierung eines österreichischen 3R Zentrums mit einem Teilstandort an der Medizinischen Universität Wien	Biomedizinische Forschung_308	Hohensinner Philipp
FA654A0101	Implementierung eines österreichischen 3R Zentrums mit einem Teilstandort an der Medizinischen Universität Wien	Biomedizinische Forschung_308	Hohensinner Philipp
FA727A0802	Randomized, Placebo-controlled, double blind multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF)-DHELIVER	Blutgruppenserologie und Transfusionsmedizin_727	Müller Antonia Maria Susanne
FA722A0204	Lipid metabolism in granulomatous diseases	Dermatologie_722	Stary Georg
FA722A0502	A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNSHINE)	Dermatologie_722	Jonak Constanze

FA722A0601	Protecting vascular barrier function across discipline and disease boundaries	Dermatologie_722	Schossleitner Kludia
FA722A0803	Allergen molecules in allergic skin disease: From pathomechanisms to diagnosis and treatment.	Dermatologie_722	Weninger Wolfgang Peter
FA722A1002	Persisting inflammation in treated atopic dermatitis skin – a potential mediator of disease recurrence.	Dermatologie_722	Brunner Patrick
FA722B1110	A Phase 3, Randomized, Double Blinded Study of Nivolumab Monotherapy of Nivolumab Combined with Ipilimumab versus Ipilimumab Monotherapy in Subjects with Previously untreated unresectable of Metastatic Melanoma - CA209-067.	Dermatologie_722	Höller Christoph
FA722B1142	A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma. (KEYVIBE-010)" (MK7684A-010, Site number 0600)	Dermatologie_722	Höller Christoph
FA722B2310	Keloid	Dermatologie_722	Mildner Michael
FA722C0435	A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection"	Dermatologie_722	Rieger Armin
FA722C0727	Safe edible insects	Dermatologie_722	Epstein Michelle

FA722C1208	Epidemiology of Hereditary Angioedema and its Subtypes in Austrian Registry of Bradykinin-mediated Angioedema	Dermatologie_722	Kinaciyar Tamar
FA722C1214	Eine offene Verlängerungsstudie zur Beurteilung der langfristigen Sicherheit von KVD900, einem oralen Plasma-Kallikrein-Inhibitor, zur Bedarfsbehandlung von Angioödem-Attacken bei jugendlichen und erwachsenen Patienten mit hereditärem Angioödem Typ I oder II	Dermatologie_722	Kinaciyar Tamar
FA722C1215	Eine doppelblinde, placebokontrollierte, randomisierte, dosisabhängige Parallelgruppenstudie der Phase II zur Beurteilung der Sicherheit und Wirksamkeit von oral verabreichtem PHA-022121 zur Prophylaxe gegen Angioödem-Attacken bei Patienten mit hereditärem Angioödem aufgrund eines C1-Inhibitor-Mangels (Typ I oder Typ II)	Dermatologie_722	Kinaciyar Tamar
FA722B1141	Phase-III-Studie zu Fianlimab (REGN3767, Anti-LAG-3-Antikörper) plus Cemiplimab versus Pembrolizumab bei Patienten mit zuvor unbehandeltem irresektablem lokal fortgeschrittenem oder metastasiertem Melanom	Dermatologie_722	Höller Christoph
FA751B0602	The Effectiveness of Real Time Continuous Glucose Monitoring to Improve Glycemic Control and Pregnancy Outcomes in Patients with Gestational Diabetes Mellitus	Frauenheilkunde_751	Göbl Christian
FA751B0801	Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial	Frauenheilkunde_751	Yerlikaya-Schatten Gülen
FA751C0131	ATALANTE - A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab	Frauenheilkunde_751	Polterauer Stephan

FA751C0622	A randomized, multicenter, open label phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy	Frauenheilkunde_751	Singer Christian
FA751C0654	A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status	Frauenheilkunde_751	Singer Christian
FA751C0659	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer CheckMate 7FL: CHECKpoint pathway and nivolumab clinical Trial Evaluation 7FL	Frauenheilkunde_751	Singer Christian
FA751C0662	Germline BRCAness in patients with ovarien and breast cancer with and without family history	Frauenheilkunde_751	Singer Christian
FA751C0667	Austrian BRCA-associated metastatic breast cancer registry	Frauenheilkunde_751	Singer Christian
FA751C0667	Austrian BRCA-associated metastatic breast cancer registry	Frauenheilkunde_751	Singer Christian
FA751C0679	Labortechniken	Frauenheilkunde_751	Singer Christian

FA751C0680	Tamoxifen im Vergleich zu Anastrozol, alleine oder in Kombination mit Zoledronat bei prämenopausalen Patientinnen mit Mammacarcinom Stadium I und II und hormonrezeptorpositivem Tumor	Frauenheilkunde_751	Singer Christian
FA751C0681	A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Pa-tients with BRCA Mutations and Early Stage HER2-Negative Breast Cancer	Frauenheilkunde_751	Singer Christian
FA751C1206	Eine epidemiologische, prospektive Beobachtungsstudie zur Erhebung von Evidenz aus der Versorgungsrealität von Patientinnen und Patienten mit HR+/HER2- Fortgeschrittenem Brustkrebs, die in der Erstlinie gemäß aktuellem Behandlungsstandard mit einer endokrin-basierten Palbociclib-Kombinationstherapie behandelt werden	Frauenheilkunde_751	Pfeiler Georg
FA751C1207	PD-L1 heterogeneity in primary and matched metastatic lesions in TNBC and HER2-enriched breast cancers	Frauenheilkunde_751	Pfeiler Georg
FA751C1209	Patient Preference for the Administration of Pelgraz by Infector (PFI) versus Needle (PFS) for the Prevention of Neutropenia in Breast Cancer Patients receiving Myelosuppressive Chemotherapy	Frauenheilkunde_751	Pfeiler Georg
FA751C1210	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 52 weeks in women with, or at high risk for developing hormone-receptor positive breast cancer	Frauenheilkunde_751	Pfeiler Georg

FA751C1211	A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer	Frauenheilkunde_751	Pfeiler Georg
FA751C1604	A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer	Frauenheilkunde_751	Polterauer Stephan
FA751C1605	A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)	Frauenheilkunde_751	Polterauer Stephan
FA751C1606	A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer	Frauenheilkunde_751	Polterauer Stephan
FA751C1802	AC2202: Observational analysis of the association of drug activity measured in viable tumour tissues ex vivo and clinical response in ovarian cancer: a basic research study	Frauenheilkunde_751	Aust Stefanie
FA751C2001	Innovative nanomaterials for detection of PIK3CA DNA point mutations for breast cancer therapy	Frauenheilkunde_751	Deutschmann Christine
FA751C2101	A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)" and any amendments thereto	Frauenheilkunde_751	Seifert Michael

FA751C2201	Tigovit, ein Grüntee Extrakt, zur Behandlung von Endometriose-assoziierten Schmerzen: eine randomisierte, doppel-blinde, placebo-kontrollierte Studie	Frauenheilkunde_751	Perricos Alexandra
FA751C2301	Etablierung einer urogynäkologischen Biobank	Frauenheilkunde_751	Palmrich Pilar
FA265A0101	New additional childcare options at the Medical University of Vienna	Gender Mainstreaming und Diversity_265	Steinböck Sandra
FA657A0102	Investigating sex-based differences in Bronze Age childcare through peptide analysis of dental enamel	Gerichtsmedizin_304	Kanz Fabian
FA744B0804	Mi2000 Vollständig Implantierbares Cochlea-Implantat - TICI Zulassungsstudie	Hals-, Nasen- und Ohrenkrankheiten_744	Riss Dominik
FA744B0903	European Real-Life Chronic Rhinosinusitis Outcome Registry	Hals-, Nasen- und Ohrenkrankheiten_744	Schneider Sven-Thorben
FA744B0904	ENLIGHTEN 1: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults	Hals-, Nasen- und Ohrenkrankheiten_744	Schneider Sven-Thorben
FA744B1104	A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab	Hals-, Nasen- und Ohrenkrankheiten_744	Brunner Markus
FA744B1601	Detaillierte molekulare Analyse von humanem Innenohrgewebe – ein Pilotprojekt	Hals-, Nasen- und Ohrenkrankheiten_744	Landegger Lukas

CD10273202	CD-Labor für Mechanische Kreislaufunterstützung	Herzchirurgie_732	Granegger Marcus
FA731C1409	Educational Grant: Advanced training in surgical therapy of congenital heart valve defects	Herzchirurgie_732	Wiedemann Dominik
FA731C2102	Intuity Database	Herzchirurgie_732	Andreas Martin
FA732A0202	Sicherheit und Wirksamkeit niedrig-energetischer elektrischer Kardioversion mit oder ohne anschließenden bi-atrialem Pacing bei Patienten mit post-operativem Vorhofflimmern im klinischen Alltag - Die DefiPace Studie	Herzchirurgie_732	Osorio Emilio
FA732A0304	Virtual Reality SIMulator and digital PORTfolio in CardioThoracic Surgery	Herzchirurgie_732	Andreas Martin
FA732A0305	Evaluation of TAVR using the NAVITOR valve in a Global Investigation - VANTAGE Study	Herzchirurgie_732	Andreas Martin
FA732A0404	Ausbildungsvertrag - VAD Coordinator Course / HeartMate 3TM LVAS Training	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0405	Non-invasive monitoring of fully magnetically levitated left ventricular assist devices – HeartMate 3 Snoopy	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0502	ShuttlePump II – Safety and efficacy assessment of a novel total artificial heart	Herzchirurgie_732	Granegger Marcus

FA732A0602	Kurzfristige Kreislaufunterstützung mit VA-ECMO (Veno-Arterielle Extrakorporale membranoxxygenierung) unter Verwendung der Eurosets ECMOLIFE Konsole an der Medizinischen Universität Wien	Herzchirurgie_732	Wiedemann Dominik
FA711A0163	A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma	Innere Medizin I_711	Preusser Matthias
FA711A0315	A randomized, placebo-controlled, double-blind, multi-center, phase III study investigating the efficacy and safety of trimodulin (BT588) as add-on therapy to standard care in adult subjects with severe community-acquired pneumonia (sCAP)	Innere Medizin I_711	Burgmann Heinz
FA711A0412	Influenza Vaccine Challenge Study	Innere Medizin I_711	Knapp Sylvia
FA711A0412	Influenza Vaccine Challenge Study	Innere Medizin I_711	Knapp Sylvia
FA711A0501	Mathematical Modelling for Microbial Community Induced Metabolic Diseases	Innere Medizin I_711	Widder Stefanie
FA711A0601	Assessment of drug-mediated mast cell activation	Innere Medizin I_711	Starkl Philipp
FA711B0475	APHINITY - A Randomized multicener, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with	Innere Medizin I_711	Preusser Matthias

	operable HER2-positive primary breast cancer		
FA711B0556	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting	Innere Medizin I_711	Preusser Matthias
FA711B0592	Personalized marker-driven early switch to aflibercept on patients with metastatic colorectal cancer (PERMAD-Trial)	Innere Medizin I_711	Preusser Matthias
FA711B0601	"A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK3475-048)"	Innere Medizin I_711	Preusser Matthias
FA711B0901	A prospective investigator-initiated translational study assessing cellfree-tumor DNA in metastasized colorectal carcinoma (mCRC) patients treated with trifluridine/tipiracil: the Triple T-Trial	Innere Medizin I_711	Preusser Matthias
FA711B0903	A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS-986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo in Combination with Chemotherapy as First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic LAG-3 Positive Gastric or	Innere Medizin I_711	Preusser Matthias

	Gastroesophageal Junction Adenocarcinoma		
FA711B0904	A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma	Innere Medizin I_711	Preusser Matthias
FA711B0918	Eine offene, randomisierte Phase-III-Studie zum Vergleich der Kombination von Trifluridin/Tipiracil (S 95005) und Bevacizumab mit der Kombination aus Capecitabin und Bevacizumab in der First-Line-Therapie bei Patienten mit metastasiertem kolorektalem Karzinom, die für eine intensiviertere Therapie nicht geeignet sind (SOLSTICE Studie)	Innere Medizin I_711	Preusser Matthias
FA711B0931	Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: A multicenter, single arm study	Innere Medizin I_711	Preusser Matthias
FA711B0933	A phase 1/2, open-label study, evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of AMG 510 Monotherapy in subjects with advanced solid tumors with KRAS p.G12C mutation and AMG 510 Combination Therapy in subjects with advanced NSCLC with KRAS p.G12C mutation	Innere Medizin I_711	Preusser Matthias

FA711B0941	a phase 3, open-label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of Pemigatinib versus Gemcitabine plus Cisplatin Chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement	Innere Medizin I_711	Preusser Matthias
FA711B0945	an open-label, two-arm, randomized, single-stage phase II study of Atezolizumab in combination with dual HER2 blockage plus epirubicin as neoadjuvant therapy for HER2-positive early breast cancer	Innere Medizin I_711	Preusser Matthias
FA711B0960	An open-label, randomised, phase-III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal cancer	Innere Medizin I_711	Preusser Matthias
FA711B0964	a phase-II, open-label, randomized, parallel arm study of NIS793 (with and without Spartalizumab) in combination with SOC chemotherapy Gemcitabine/nab-Paclitaxel, and Gemcitabine/nab-Paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) - interner Studiencode CNIS793B12201	Innere Medizin I_711	Preusser Matthias
FA711B0999	Observational study for assessing treatment and outcome of patients with primary brain tumors diagnosed according to cIMPACT-NOW recommendations and the 2021 WHO classification	Innere Medizin I_711	Preusser Matthias
FA711B1001	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in	Innere Medizin I_711	Preusser Matthias

	Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1		
FA711B1002	Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing brain metastases	Innere Medizin I_711	Preusser Matthias
FA711B1003	RO-IIS-2020-20598//RO5541077 ML42274 - Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients with relapsed / refractory Mantle Cell Lymphoma - a Single Center Phase II Trial	Innere Medizin I_711	Preusser Matthias
FA711B1004	Epidemiology and Treatment Patterns of MSI-H/dMMR Solid Tumors in Austria: A Retrospective Cohort Study in 4 Academic Centers	Innere Medizin I_711	Preusser Matthias
FA711B1005	A phase II trial Cabozantinib in patients with advanced, low proliferative NEN G3	Innere Medizin I_711	Preusser Matthias
FA711B1006	Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA	Innere Medizin I_711	Preusser Matthias
FA711B1007	EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestran vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2-Early Breast Cancer with an Increased Risk of Recurrence	Innere Medizin I_711	Preusser Matthias

FA711B1008	A randomized, open-labelled, Phase-3 study of Sacituzumab Govitecan and Pembrolizumab versus treatment of physician's choice and Pembrolizumab in patients with previously untreated, locally advanced inoperable or metastatic trip-neg Breast Cancer, whose tumors express PD-L1	Innere Medizin I_711	Preusser Matthias
FA711B1009	A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma	Innere Medizin I_711	Preusser Matthias
FA711B1010	ABCSG-55N / AMBHER: Description of patients with HER2 positive breast cancer undergoing neoadjuvant treatment and development of a dynamic composite risk score to predict the risk of distant recurrence	Innere Medizin I_711	Preusser Matthias
FA711B1011	EU HORIZON EORTC 2227-BTG: Lomustine with or without reirradiation for first progression of glioblastoma: a randomized phase III study (LEGATO)	Innere Medizin I_711	Preusser Matthias
FA711B1012	Austrian registry for evaluation of treatment patterns and outcome in patients with advanced pancreatic ductal adenocarcinoma (PDAC)	Innere Medizin I_711	Preusser Matthias
FA711B1013	Eine unverblindete Erweiterungsstudie der Phase 2 bei Prostatakrebs-Patienten, die zuvor an einer klinischen Studie zu Enzalutamid teilgenommen haben	Innere Medizin I_711	Preusser Matthias
FA711B1014	An open-label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma	Innere Medizin I_711	Preusser Matthias

FA711C0363	„Nicht-interventionelle Studie (NIS) zur Langzeitbeobachtung der Behandlung von Hämophilie A Patienten mit Haemoctin® SDH" mittels elektronischer Dokumentation.	Innere Medizin I_711	Pabinger Ingrid
FA711C0639	AN OPEN LABEL, RANDOMIZED (2:1) PHASE 2B STUDY OF DASATINIB VS. IMATINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA WHO HAVE NOT ACHIEVED AN OPTIMAL RESPONSE TO 3 MONTHS OF THERAPY WITH 400 MG IMATINIB	Innere Medizin I_711	Valent Peter
FA711C0674	Einsatz von Pomalidomid (Imnovid(R)) beim Relapsiert/Refraktären Multiplen Myelom unter Praxisbedingungen	Innere Medizin I_711	Valent Peter
FA711C0910	Analysis of serologic and molecular markers and their relation to therapy to optimize personalized medicine strategies in AML: A Registry Study	Innere Medizin I_711	Valent Peter
FA711C0910	Analysis of serologic and molecular markers and their relation to therapy to optimize personalized medicine strategies in AML: A Registry Study	Innere Medizin I_711	Valent Peter
FA711C0924	M20-356 study, Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring Chronic Lymphocytic Leukemia	Innere Medizin I_711	Valent Peter
FA711C0925	Thromboembolic risk and mortality of patients with Cold Agglutinin Disease (CAD) in European countries: A Retrospective Chart review	Innere Medizin I_711	Valent Peter
FA711C0926	Wirksamkeit und Sicherheit von Carfilzomib in Kombination mit Ibrutinib oder Ibrutinib alleine bei Patienten mit Morbus Waldenström (CZAR-1)	Innere Medizin I_711	Valent Peter

FA711C0927	A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis	Innere Medizin I_711	Valent Peter
FA711C0928	Telemedical support of patients with multiple myeloma during the COVID19 pandemia using the ESMART@HOME system	Innere Medizin I_711	Valent Peter
FA711C0929	A Prospective, Open-Label, Multicenter, Randomized, Phase 3 Trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients with High Risk (17p-deletion, TP53- mutation or complex karyotype) Chronic Lymphocytic Leukemia (CLL)	Innere Medizin I_711	Valent Peter
FA711C0930	M20-621 STUDY, A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE SAFETY AND EFFICACY OF EPCORITAMAB IN COMBINATION WITH R-CHOP COMPARED TO R-CHOP IN SUBJECTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA	Innere Medizin I_711	Valent Peter
FA711C0930	M20-621 STUDY, A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE SAFETY AND EFFICACY OF EPCORITAMAB IN COMBINATION WITH R-CHOP COMPARED TO R-CHOP IN SUBJECTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA	Innere Medizin I_711	Valent Peter
FA711C0931	A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia vera	Innere Medizin I_711	Valent Peter

FA711C0932	AGIOSA Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Double-blind, Randomized, Placebo-Controlled (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes	Innere Medizin I_711	Valent Peter
FA711C0933	Eine mehrteilige, randomisierte, doppelblinde, placebokontrollierte klinische Studie der Phase II zur Sicherheit und Wirksamkeit von CGT9486 bei Patienten mit nicht fortgeschrittener systemischer Mastozytose	Innere Medizin I_711	Valent Peter
FA711C0934	A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy	Innere Medizin I_711	Valent Peter
FA711C0935	R-Pola-Glo - A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R CHOP	Innere Medizin I_711	Valent Peter
FA711C1033	A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (Rve) versus obinutuzumab (GA101) plus venetoclax (Gve) versus obinutuzumab (GA101) plus ibrutinib plus venetoclax (GIVE) with previously untreated chronic lymphocytic leukemia (CLL) without Del(17p) or TP53 mutation	Innere Medizin I_711	Valent Peter

FA711C1042	A prospective, non-interventional biomedical research study of genetic aberrations and immunity in myeloproliferative neoplasms	Innere Medizin I_711	Valent Peter
FA711C1043	A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma	Innere Medizin I_711	Jäger Ulrich
FA711C1049	A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia	Innere Medizin I_711	Jäger Ulrich
FA711C1061	NIVEAU Study - DSHNHL 2015-1: Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma	Innere Medizin I_711	Jäger Ulrich
FA711C1067	A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH CHOP OR CHPPOLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA	Innere Medizin I_711	Jäger Ulrich
FA711C1070	NAVIFY Tumor Board-Lösung - Pilotprojekt	Innere Medizin I_711	Jäger Ulrich

FA711C1074	Eine prospektive, randomisierte, kontrollierte, offene, multizentrische, in zwei Abschnitte gegliederte Crossover-Studie der Phase III mit einer aus einem einzigen Arm bestehenden Fortsetzung zur Beurteilung der Sicherheit und Wirksamkeit von BAX 930 (rADAMTS13) bei der prophylaktischen und Bedarfsbehandlung von Patienten mit schwerer kongenitaler thrombotisch thrombozytopenischer Purpura (cTTP, Upshaw-Schulman-Syndrom USS, hereditäre thrombotisch thrombozytopenische Purpura, hTTP)	Innere Medizin I_711	Valent Peter
FA711C1079	ESMART: Supporting Myeloma Patients using the Advanced Symptom Management System (ASYMS) Remote Technology	Innere Medizin I_711	Valent Peter
FA711C1098	A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia	Innere Medizin I_711	Valent Peter
FA711C1201	Laboratory measurements for monitoring the treatment of patients with hemophilia treated with FVIII-, FIX-replacement therapies and non-factor therapeutics	Innere Medizin I_711	Königsbrügge Oliver
FA711C1302	Consulting Services Agreement – JCAR017-BCM-001	Innere Medizin I_711	Jäger Ulrich
FA711C1319	Hämatologiekurs 2023	Innere Medizin I_711	Jäger Ulrich

FA711C1410	Eine multinationale, multizentrische, prospektive Kohortenstudie zur Beurteilung der Seroprävalenz und Serokonversion von Antikörpern gegen Serotypen des Adeno-assoziierten Virus (AAV) bei Patienten mit Hämophilie A	Innere Medizin I_711	Ay Cihan
FA711C1411	Eine multizentrische, randomisierte, offene Phase-III-Studie, mit verblindeter Auswertung der Zielparameter, die die Wirkung von Abelacimab im Verhältnis zu Apixaban auf wiederkehrende venöse Thromboembolien (VTE) und Blutungen bei Patienten mit krebsbedingten VTE vergleicht (ASTER)	Innere Medizin I_711	Ay Cihan
FA711C1412	Eine multizentrische, randomisierte, offene Phase-III-Studie, mit verblindeter Auswertung der Zielparameter, die die Wirkung von Abelacimab im Verhältnis zu Dalteparin auf wiederkehrende venöse Thromboembolien (VTE) und Blutungen bei Patienten mit gastrointestinalem (GI)/urogenitalem (GU) Karzinom im Zusammenhang mit VTE vergleicht (Magnolia)	Innere Medizin I_711	Ay Cihan
FA711C1413	Bestimmung des biologischen Alters von Patienten mit Hämophilie A mittels einer etablierten epigenetischen Uhr	Innere Medizin I_711	Ay Cihan
FA711C1501	Estimating Risk of Selected Adverse Events in Patients with Von Willebrand Disease Treated with VEYVONDI® (vonico g alfa; recombinant Von Willebrand Factor)	Innere Medizin I_711	Eichinger-Hasenauer Sabine
FA711C1502	A prospective, non-interventional biomedical research study of genetic aberrations and immunity in Myeloproliferative Neoplasms and Immune thrombocytopenic purpura	Innere Medizin I_711	Eichinger-Hasenauer Sabine

FA711D0316	A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with moderate or severe COVID-19.	Innere Medizin I_711	Burgmann Heinz
FA711D0317	Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community acquired pneumonia. A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22)	Innere Medizin I_711	Burgmann Heinz
FA711D0502	EU HJU Enabling the WHO-Roadmap 2030	Innere Medizin I_711	Lell Bertrand
FA711E0103	Grant Grünenthal	Innere Medizin I_711	Masel Eva
UE71106013	Spende der Amgen GmbH – Personalkostenförderung	Innere Medizin I_711	Pabinger Ingrid
FA711C1408	Eine multizentrische, prospektive, offene, unkontrollierte Phase-III-Studie zur Beurteilung der Wirksamkeit, Sicherheit und Pharmakokinetik von Alternativ bei Patient*innen mit angeborenem Antithrombinmangel, die sich einer Operation unterziehen, oder bei der Entbindung	Innere Medizin I_711	Ay Cihan
FA711C1409	A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2) - CVAY36Q123-1	Innere Medizin I_711	Ay Cihan

FA714B0391	An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH	Innere Medizin II_714	Lang Irene
FA714B0392	A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study	Innere Medizin II_714	Lang Irene
FA714B0393	IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)	Innere Medizin II_714	Lang Irene
FA714B1524	SPIRonolactone In the Treatment of Heart Failure - SPIRIT-HF	Innere Medizin II_714	Kastner Johannes
FA714B1714	CALLIOPE - AUT WIE3	Innere Medizin II_714	Gwechenberg er Marianne
FA714B2015	A phase 1b double-blind, randomized, placebo-controlled, multicenter, dose titration study to evaluate the safety, tolerability, and pharmacokinetics of 4 weeks treatment with BAY 2413555 in participants with heart failure and implanted cardiac defibrillator or cardiac resynchronization devices“, (REMOTE-HF)	Innere Medizin II_714	Hülsmann Martin
FA714B2305	A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)	Innere Medizin II_714	Siller-Matula Jolanta

FA714B2904	Educational Grant - Mitralklappenprogramm	Innere Medizin II_714	Bartko Philipp Emanuel
FA714B3104	Eine multizentrische, randomisierte, doppelt-verblindete, Parallelgruppen- und Placebo- kontrollierte Studie zur Untersuchung der Wirksamkeit und Sicherheit von Finerenone bei Patienten mit Herzinsuffizienz (NYHA II-IV) und linksventrikulärer Auswurfraction $\geq 40\%$ (LVEF \geq 40%), FINEARTS-HF	Innere Medizin II_714	Kastner Johannes
FA714B3108	Optimizing Beta Blocker Dosage in Women Using the Wearable Cardioverter Defibrillator - OPT-BB Women	Innere Medizin II_714	Kastner Johannes
FA714B3112	A phase 3, Randomized, Multicenter, Double-Blind, Placebo Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis	Innere Medizin II_714	Kastner Johannes
FA714B4212	Educational Grant	Innere Medizin II_714	Hengstenberg Christian
FA714B4305	A Double blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olapasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)	Innere Medizin II_714	Speidl Walter
FA714B4702	Einfluss der Diabetes-Medikation auf den Krankheitsverlauf in Patienten mit Herzinsuffizienz vom HFpEF-Typ	Innere Medizin II_714	Badr Eslam Roza

FA714B4703	doppelblinde, randomisierte, Placebo-kontrollierte, multizentrische, internationale Parallelgruppenstudie der Phase III zur Beurteilung der Sicherheit, Verträglichkeit und Wirksamkeit von Mavacamten im Vergleich zu Placebo bei Teilnehmern mit symptomatischer nHCM (nichtobstruktiver, hypertrophischer Kardiomyopathie (non-obstructive Hypertrophic Cardiomyopathy))	Innere Medizin II_714	Badr Eslam Roza
FA714B4910	A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Innere Medizin II_714	Kastl Stefan
FA714B5801	"Novel biomarkers"	Innere Medizin II_714	Mayr Manuel
FA714C0316	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) - OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And Lipoprotein(a) reduction – Outcomes trial	Innere Medizin II_714	Schernthaner Gerit
FA714C0317	Non-interventional study on the treatment with bempedolc acid and/or its fixed-dose combination with ezetimibe in routine clinical practice in patients with primary hypercholesterolemia Or mixed dyslipidemia (MILOS).	Innere Medizin II_714	Schernthaner Gerit

FA714C0711	Evaluation of Safety and Efficacy of the S.M.A.R.T. RADIANT Vascular Stent System in the treatment of Iliac and Femoropopliteal Lesions via Transradial Access	Innere Medizin II_714	Schlager Oliver
FA714C0712	Bolt Lithotripsy RESTORE ATK Trial for PAD (RESTORE ATK)	Innere Medizin II_714	Schlager Oliver
FA714C0801	A randomized trial comparing the ELUVIA TM drug-eluting stent versus bare Metal self-expanding Nitinol-Stents in the treatment of superficial femoral and/or proximal popliteal arteries	Innere Medizin II_714	Gschwandtner Michael
FA714D0504	Wirksamkeit und Sicherheit von Benralizumab im Real-World Setting in Patienten mit schwerem eosinophilem Asthma in Wien - (BEHAVE) 1.1. Projekttitle (Englisch): The real-world effectiveness and safety of Benralizumab in patients with severe eosinophilic asthma in Vienna – (BEHAVE)	Innere Medizin II_714	Idzko Marco
FA714D0506	Eine prospektive, nicht-interventionelle, multizentrische Beobachtungsstudie zur Bewertung der Wirksamkeit, des Anwendungsmusters und der subjektiv von Patienten angegebenen Ergebnisse von Dupilumab unter Alltagsbedingungen bei Patienten mit schwerem unzureichend kontrolliertem Asthma-ProVENT	Innere Medizin II_714	Idzko Marco
FA714D0507	BI 1015550 (1305-0014 und 1305-0023)	Innere Medizin II_714	Idzko Marco
FA714D0802	IMPALLA - IMPAct of ArtiQ.PFT, an artificial intelligence bAsed data interpretation tool, on improving the diagnosis and referral process for ILD patients.	Innere Medizin II_714	Gompelmann Daniela

UE71406007	Drittmittelfinanzierung Study Nurse	Innere Medizin II_714	Lang Irene
FA716B0309	GOS 52621-06	Innere Medizin III_716	Scherer Thomas
FA716B0621	Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes.	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B0622	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity.	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B1310	Evaluation of long-term complications after bariatric surgery - A questionnaire-based long-term follow-up pilot study	Innere Medizin III_716	Krebs Michael
FA716B1405	Thiazide treatment in permanent hypoparathyroidism	Innere Medizin III_716	Vila Greisa
FA716B1502	Novel Metabolic Muscular Biomarkers in Pompe disease - a non invasive magnetic resonance pilot study	Innere Medizin III_716	Scherer Thomas
FA716B1602	Investigating the impact of pharmacological restauration of circadian cortisol rhythm by metyrapone on cardiometabolic risk factors in patients with autonomous adrenal cortisol secretion.	Innere Medizin III_716	Wolf Peter
FA716C0820	Otsuka ADPKD Bone 19317	Innere Medizin III_716	Sunder-Plaßmann Gere

FA716C0824	A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease	Innere Medizin III_716	Sunder-Plaßmann Gere
FA716C0916	A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an anti-CD2 monoclonal antibody, TCD601 (siplizumab) compared to anti-thymocyte globulin (rATG), as induction therapy in de novo Renal Transplant Recipients)	Innere Medizin III_716	Böhmig Georg
FA716C1021	Recombinant SARS-CoV-2-antibodies in kidney transplant recipients without neutralizing antibody response following full vaccination	Innere Medizin III_716	Oberbauer Rainer
FA716C2504	Donor derived circulating cell free DNA in combination with Torque Teno virus plasma load for the detection of allo-immunity in kidney grafts - a secondary analysis of the TTV guideIT trial	Innere Medizin III_716	Bond Gregor
FA716D0714	A 48-week, 6-arm, randomized, double-blind, placebocontrolled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations of patients with Sjögren`s Syndrome (TWINSS) CCFZ533B2201	Innere Medizin III_716	Scheinecker Clemens
FA716D0718	Förderung des Aufbaues einer umfangreichen Datenbank zur translationalen Forschung auf dem Gebiet der Immundefekte	Innere Medizin III_716	Scheinecker Clemens
FA716D0718	Förderung des Aufbaues einer umfangreichen Datenbank zur translationalen Forschung auf dem Gebiet der Immundefekte	Innere Medizin III_716	Scheinecker Clemens

FA716D0904	EU Innovative Medicines Initiative 2 Joint Undertaking H2020 - JTI-IMI2	Innere Medizin III_716	Aletaha Daniel
FA716D1403	Schwangerschaftsregister für Patientinnen mit rheumatischen Erkrankungen & Familienplanung/- Gründung	Innere Medizin III_716	Mazzucato- Puchner Antonia
FA716D1503	Interleukin 17 and osteoclastogenesis in psoriatic arthritis: The effects of IL-17 blockade	Innere Medizin III_716	Hayer Silvia
FA716E0843	AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144	Innere Medizin III_716	Trauner Michael
FA716E0855	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo- Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Innere Medizin III_716	Trauner Michael
FA716E0855	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo- Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Innere Medizin III_716	Trauner Michael
FA716E0968	WO41535 - A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION	Innere Medizin III_716	Trauner Michael

FA716E0983	INTEGRIN SIGNALING IN LIVER FIBROSIS	Innere Medizin III_716	Trauner Michael
FA716E0983	INTEGRIN SIGNALING IN LIVER FIBROSIS	Innere Medizin III_716	Trauner Michael
FA716E1028	ML44459 - Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in patients with Hepatocellular Carcinoma who failed to respond to prior immunotherapy - the FAB-HCC Trial	Innere Medizin III_716	Trauner Michael
FA716E1029	COMBINED ACTIVE TREATMENT IN TYPE 2 DIABETES WITH NASH	Innere Medizin III_716	Trauner Michael
FA716E1030	3004A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis	Innere Medizin III_716	Trauner Michael
FA716E1031	A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn`s Disease	Innere Medizin III_716	Trauner Michael
FA716E1032	A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis	Innere Medizin III_716	Trauner Michael

FA716E1033	A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)"	Innere Medizin III_716	Trauner Michael
FA716E1034	GALOCEAN: A prospective, non-interventional, multi-country cohort study of the effectiveness and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis	Innere Medizin III_716	Trauner Michael
FA716E1035	characterization of liquid biomarkers in patients with advanced chronic liver disease and portal hypertension	Innere Medizin III_716	Trauner Michael
FA716B2001	Investigation of nutritional supplements on metabolism in patients with diabetes mellitus type 2	Innere Medizin III_716	Leutner Michael
FA716E1027	Closing the diagnostic and therapeutic gaps in HDV at the General Hospital Vienna	Innere Medizin III_716	Trauner Michael
CD10278101	"CD-Labor für Molekulare Stressforschung in der Peritonealdialyse. ("Christian Doppler Laboratory for Molecular Stress Research in Peritoneal Dialysis""")"	Kinder- und Jugendheilkunde_781	Kratochwill Klaus
FA781B1402	Jeffrey Modell Immunodeficiency Center @ MedUni Vienna	Kinder- und Jugendheilkunde_781	Förster-Waldl Elisabeth
FA781B1602	Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study	Kinder- und Jugendheilkunde_781	Azizi Amedeo

FA781B1603	LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial Of DAY101 Monotherapy Versus Standard Of Care Chemotherapy In Patients With Pediatric Low-Grade Glioma Harboring An Activating RAF Alteration Requiring First-Line Systemic Therapy	Kinder- und Jugendheilkunde_781	Azizi Amedeo
FA781B2204	“MEIN LOGBUCH! – ICH KENNE MICH AUS!” Quality Improvement Projekt - ein Beitrag zur Implementierung und Evaluierung der aktualisierten S3-Leitlinie zur psychosozialen Versorgung in der Pädiatrischen Onkologie und Hämatologie. Entwicklungs- und Pilotphase	Kinder- und Jugendheilkunde_781	Weiler-Wichtl Liesa
FA781B2401	Phase I/II open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged ≥ 1 year to < 18 years with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours with known ErbB pathway deregulation regardless of tumour histology	Kinder- und Jugendheilkunde_781	Peyrl Andreas
FA781B3002	Innovative intraosseous drill: NeON (Neonatal IntraOsseous Needle) for safe use in newborn emergencies	Kinder- und Jugendheilkunde_781	Schwindt Eva
FA781B3504	EPILEPSY-RARE Vienna - Seltene EPILEPSIen bei Kindern und Jugendlichen – Prospektives Register zur Beschreibung des Verlaufs, der Anfallslast und des Outcomes kindlicheR Epilepsiesyndrome an der Medizinischen Universität Wien.	Kinder- und Jugendheilkunde_781	Male-Dressler Anastasia
FA781B3601	ReConNect: RemoteConsulting4NeonatalResuscitation - eine simulationsbasierte Pilotstudie	Kinder- und Jugendheilkunde_781	Rittenschober-Böhm Judith

FA781B3701	Babysensor-Pre project	Kinder- und Jugendheilkunde_781	Giordano Vito
FA781D0444	Multizentrische, offenen Studie zur Untersuchung der Wirksamkeit und Sicherheit von AOP Landiolol zur Regulierung supraventrikulärer Tachykardien bei pädiatrischen Patienten (LANDI-PED)	Kinder- und Jugendheilkunde_781	Michel-Behnke Ina
FA781D0613	*An open-label study in pediatric, severe hemophilia A participants with or without inhibitors or moderately severe to severe hemophilia B participants with or without inhibitors comparing 12 months of historical standard treatment to Marstacimab prophylaxis	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781F0116	A multicentre, non-interventional study to evaluate long-term safety in patients with achondroplasia treated with Voxzogo® (vosoritide)	Kinder- und Jugendheilkunde_781	Hartmann Gabriele
FA781F0210	Early allergen-specific immunotherapy to prevent the development of allergy	Kinder- und Jugendheilkunde_781	Szépfolusi Zsolt
FA781F0213	A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma	Kinder- und Jugendheilkunde_781	Szépfolusi Zsolt
FA781F0214	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis	Kinder- und Jugendheilkunde_781	Szépfolusi Zsolt
FA781F0603	A Global, Multi-Center, Long-Term, Observational Survey of Patients with Hunter Syndrome (Mucopolysaccharidosis II)	Kinder- und Jugendheilkunde_781	Konstantopoulou Vassiliki

FA781F1302	Eine offene Studie der Phase III zur Beurteilung der langfristigen Sicherheit und Wirksamkeit der VX 445 Kombinationstherapie bei Patienten mit zystischer Fibrose, die homozygot oder heterozygot für die F508del-Mutation sind	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt
FA781F1604	Metachromatische Leukodystrophie Neugeborenen-Screening Pilotprogramm (MLD-NBS)	Kinder- und Jugendheilkunde_781	Zeyda Maximilian
FA781F1801	Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age with Generalized Myasthenia Gravis	Kinder- und Jugendheilkunde_781	Siegert Sandy
FA781F1901	Rare disease educAtional pRogram for children	Kinder- und Jugendheilkunde_781	Vodopiutz Julia
FA781F1902	Rare disease educAtional pRogram for children	Kinder- und Jugendheilkunde_781	Vodopiutz Julia
FA781F1903	Rare disease educAtional pRogram for children	Kinder- und Jugendheilkunde_781	Vodopiutz Julia
FA781F2001	Reconstruction and Computational Modelling for Inherited Metabolic Diseases	Kinder- und Jugendheilkunde_781	Möslinger Dorothea
FA781F2101	Innovative digitale Messmethoden zur Feststellung der Fahrtüchtigkeit	Kinder- und Jugendheilkunde_781	Felnhofer Anna
FA781G0112	IMPROVE – PD: Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis	Kinder- und Jugendheilkunde_781	Aufricht Christoph

FA781G0113	Secondary Analysis of data of the phase II trial to evaluate efficacy of PD-protec® in peritoneal dialysis in patients with chronic renal failure – MAPE3	Kinder- und Jugendheilkunde_781	Aufricht Christoph
FA781G0602	An 18-month, open-label, single-arm safety extension study of an age-and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria. (FIONA-OLE)	Kinder- und Jugendheilkunde_781	Heindl-Rusai Krisztina
FA781G0901	ClopiD4FSGS	Kinder- und Jugendheilkunde_781	Daniel-Fischer Lisa
FA781G0901	ClopiD4FSGS	Kinder- und Jugendheilkunde_781	Daniel-Fischer Lisa
FW781B0101	Deciphering cell communication networks to fight ETMR	Kinder- und Jugendheilkunde_781	Senfter Daniel
UE78106007	OKids	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
UE78106021	Neurofeedback bei Neurofibromatose	Kinder- und Jugendheilkunde_781	Pletschko Thomas
FA729A0262	Follow-up study for patients having received fluPHPVE6E7 in clinical studies	Klinische Pharmakologie_729	Wolzt Michael
FA729A0553	Entsendung von B. Blöchl-Daum als Vertreterin im Committee for Orphan Medicinal Products (COMP)	Klinische Pharmakologie_729	Zeitlinger Markus

FA729A1036	Training towards Personalized Antibiotic Treatment (TIPAT)	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1047	Single dose pharmacokinetics of cefiderocol in plasma and soft tissues of healthy volunteers	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1054	A single center, open-label study to investigate the penetration of rifabutin into the lung after multiple intravenous administrations of BV100(rifabutin for infusion) in healthy participants	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1055	Antibiotics TDM in Action	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1056	A single center, open-label study to investigate the penetration of rifabutin into the lung after multiple intravenous administration of BV100 (rifabutin for infusion) in healthy participants	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1106	Phase 1a study of VGA039 in healthy volunteers and patients with von Willebrand Disease	Klinische Pharmakologie_729	Schörgenhofer Christian
FA729A1601	A Single/Multiple Ascending Dose Phase 1 Study Of The Safety, Tolerability, And Pharmacokinetics Of Intranasal 2-Deoxy-D-Glucose In Normal Healthy Volunteers	Klinische Pharmakologie_729	Haiden Nadja
FA729A1601	A Single/Multiple Ascending Dose Phase 1 Study Of The Safety, Tolerability, And Pharmacokinetics Of Intranasal 2-Deoxy-D-Glucose In Normal Healthy Volunteers	Klinische Pharmakologie_729	Haiden Nadja
FA712A1102	Bacterial ghosts as immune-stimulating adjuvant to chemotherapy in pancreatic ductaladenocarcinoma	Krebsforschung_712	Heffeter Petra

FA712A1902	Pallas ABCSG 42 Clinical Trial	Krebsforschung_712	Barozzi Iros
FA712A2001	EU HORIZON Deciphering the antibody-microbiota axis in early life	Krebsforschung_712	Vogl Thomas
FW712A0101	FWF Transformation of Pre-Clinics into Clinics by Organoids	Krebsforschung_712	Mikulits Wolfgang
FA793A0337	Baxalta field study	Labormedizin_793	Quehenberger Peter
FA793A0338	TAK-577, Analytical Reports	Labormedizin_793	Quehenberger Peter
FA793A0808	Oxitope Thrombosis	Labormedizin_793	Binder Christoph
FA793A0809	Investigating the effects of Trimodulin in Coagulation and Thrombosis	Labormedizin_793	Binder Christoph
FA793A0810	Preclinical development of a 3rd-generation interleukin-2 targeted to inflammatory sites	Labormedizin_793	Binder Christoph
FA793A1905	Alpha-1 sample analysis	Labormedizin_793	Haslacher Helmuth
FA793A2201	Innovative strategies for cancer prevention with focus on sex hormone signaling and chronic inflammation	Labormedizin_793	Wagner Erwin Friedrich

FA793A2401	Identification of clinical, genetic and immunosuppressive factors predisposing to non-melanoma skin cancer (NMSC) in immunosuppressed organ transplant recipients compared to controls – a case-control study	Labormedizin_793	Sunder-Plaßmann Raute
FA793B0121	Sensititre™ Susceptibility Plates 510k Clinical Trial for Breakpoint Compliance	Labormedizin_793	Willinger Birgit
FA793B0311	Analytical evaluation of molecular biological tests (in vitro diagnostics) for the detection of fungal pathogens directly in clinical samples	Labormedizin_793	Makristathis Athanasios
FA602A0121	EU HORIZON Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance	Medical Data Science_303	Stamm Tanja
FA660A1502	Schätzung eines statistischen Modells für die Ableitung von Alters-, Geschlechts- und Schulbildungs-abhängigen z-scores (Standard deviation scores) für eine Variable aus dem psychometrischen Test VVT 3.0.	Medical Data Science_303	Gleiss Andreas
FA618A0210	Rom1 as a fungal sensing factor during skin colonization of the human fungal pathogen <i>Candida auris</i>	Medizinische Biochemie_305	Kuchler Karl
FA618A0501	PHLPP – elucidating the mechanism of action of a tumor suppressor phosphatase	Medizinische Biochemie_305	Leonard Thomas Ashley
FW618A0101	RNA@core: "Molecular mechanisms in RNA biology"	Medizinische Biochemie_305	Martinez Javier Augusto
FA616A0404	WWTF UIP - Flying Hirsch	Medizinische Biochemie_305	Köhler Alwin

FA605A0703	Development and application of implantable pulse generator for neuromuscular activation in mice	Medizinische Physik und Biomedizinische Technik_340	Lanmüller Hermann
FA605A1302	Optical imaging platform for high-throughput longitudinal studies of the eye in disease models	Medizinische Physik und Biomedizinische Technik_340	Baumann Bernhard
FA605A1908	New patient-specific surgical simulator	Medizinische Physik und Biomedizinische Technik_340	Moscato Francesco
FA605A2002	Ultraschall-Translationsinvarianz für Bildgütephantome	Medizinische Physik und Biomedizinische Technik_340	Hummel Johann
FA605A2303	Blood Trauma testing of an axial pump	Medizinische Physik und Biomedizinische Technik_340	Schima Heinrich
FA605A2403	MR Plus - HF Labor 2	Medizinische Physik und Biomedizinische Technik_340	Frass Roberta
FA605A2404	MR Plus - HF Labor	Medizinische Physik und Biomedizinische Technik_340	Frass Roberta
FA605A2405	MR Plus - Simulation	Medizinische Physik und Biomedizinische Technik_340	Frass Roberta
FA605A2502	Kompaktes durchstimmbares Kurzpulsmodul mit zwei Ausgängen für die multimodale optische Bildgebung	Medizinische Physik und Biomedizinische Technik_340	Unterhuber Angelika
FA605A2902	Breast MRI with a flexible radio frequency coil vest: in vivo technical and clinical performance evaluation	Medizinische Physik und Biomedizinische Technik_340	Nohava Lena

FA605A3001	Rb-PET-PRC: Positron range correction for cardiac Rubidium PET	Medizinische Physik und Biomedizinische Technik_340	Rausch Ivo
FA605A3003	Material Transfer Agreement	Medizinische Physik und Biomedizinische Technik_340	Rausch Ivo
FA605A3101	Investigate sub-surface damages in optical substrate samples	Medizinische Physik und Biomedizinische Technik_340	Lichtenegger Antonia
FA605A3301	Advanced modular software engines for precision molecular imaging	Medizinische Physik und Biomedizinische Technik_340	Shiyam Sundar Lalith Kumar
FA605A3302	Data-centric software framework: Multi-organ objective segmentation	Medizinische Physik und Biomedizinische Technik_340	Beyer Thomas
FA605A3401	Künstliche Arterien	Medizinische Physik und Biomedizinische Technik_340	Grasl Christian
FA605A3402	Künstliche Arterien	Medizinische Physik und Biomedizinische Technik_340	Grasl Christian
FA605A3501	“The human central pattern generator for locomotion: Identification of its key neurons, monoaminergic receptor expression, and structural plasticity following spinal cord injury”	Medizinische Physik und Biomedizinische Technik_340	Minassian Karen
FA632A0602	Hospital Care following ICU stay (NutritionDay)	Medizinische Statistik, Informatik und Intelligente Systeme_303	Hiesmayr Jörg Michael

FA632A0602	Hospital Care following ICU stay (NutritionDay)	Medizinische Statistik, Informatik und Intelligente Systeme_303	Hiesmayr Jörg Michael
FA632A0604	nutritionDay	Medizinische Statistik, Informatik und Intelligente Systeme_303	Hiesmayr Jörg Michael
FA660A0805	Implementation for the Action "European Health Data & Evidence Network"	Medizinische Statistik, Informatik und Intelligente Systeme_303	Dufts Schmid Georg
FA660A1105	Neuentwicklung eines Cardiac-Allocation-Scores (CAS)	Medizinische Statistik, Informatik und Intelligente Systeme_303	Heinze Georg
FA602A0120	Being Equipped to Tackle Epidemics Right	Medizinische Statistik, Informatik und Intelligente Systeme_303	Stamm Tanja
FA736A0801	Evaluation of Sutability of Cold Ablation Robot Guided Laser Osteotomy for Stereoelectroencephalography (SEEG) Surgical Procedures in Sheep	Neurochirurgie_736	Rössler Karl
FA736A0801	Evaluation of Sutability of Cold Ablation Robot Guided Laser Osteotomy for Stereoelectroencephalography (SEEG) Surgical Procedures in Sheep	Neurochirurgie_736	Rössler Karl
FA761A1123	1.) Serum Neurofilament light chains as a marker for neurological manifestation in Fabry Disease 2.) Neuroinflammation in Fabry Disease and Gaucher Disease: histopathological examination in human brains	Neurologie_761	Berger Thomas
FA761A1156	A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female	Neurologie_761	Berger Thomas

	participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA		
FA761A1157	Early vs. late Ofatumumab (Kesimpta) treatment in Austrian RMS-patients over 2 years - a non interventional observational study	Neurologie_761	Berger Thomas
FA761A1158	A long-term extension of the ARGX-117-2002 trial to evaluate the long-term safety and tolerability, efficacy, Pharmacodynamics, Pharmacokinetics and Immunogenicity of ARGX-117 in adults with multifocal motor neuropathy	Neurologie_761	Berger Thomas
FA761A1159	A phase III, randomized, double-blind, placebo-controlled, multicenter basket study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Satralizumab in patients with anti-N-methyl-D-Aspartic acid receptor (NMDAR) or anti-Leucine-rich glioma-inactivated 1 (LGI1) encephalitis (CIELO)	Neurologie_761	Berger Thomas
UE76106006	Nicht-interventionelle Studie der ÖKSG: Monoklonale Antikörper zur Migräneprophylaxe	Neurologie_761	Berger Thomas
UE79606003	Determining autoimmunity in seronegative myasthenic syndromes: Prevalence of patients with autoantibodies against clustered acetylcholine receptor, MuSK or muscle cells within the D-A-CH region	Neurologie_761	Koneczny Inga
FA796A0116	Kofinanzierung Orphanet Data for Rare Diseases (OD4RD)	Neurologie_761	Voigtlaender Till

FA796A0115	Orphanet Data for Rare Diseases	Neurologie_761	Voigtlaender Till
FA761A0801	Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled Trial of thrombolysis with low doses Tenecteplase (TNK-tPA) versus Standard of care in the prevention of disability at 3 months in minor ischemic stroke with proven acute symptomatic occlusion	Neurologie-Klinik_761	Greisenegger Stefan
FA761A1116	A phase 4 randomized clinical trial of Andexanet Alfa (Andexanet Alfa for Injection) in acute intracranial hemorrhage in patients receiving an oral factor Xa inhibitor.	Neurologie-Klinik_761	Berger Thomas
FA728A1302	Prospective Evaluation of the European Society of Cardiology 0/1h-algorithm's Safety and Efficacy for Triage of Patients with Suspected Myocardial Infarction	Notfallmedizin_728	Roth Dominik
UE72806002	Machbarkeitsstudie: Digitale Notfallversorgung für Pflegeheim-Bewohner:innen	Notfallmedizin_728	Schreiber Wolfgang
FA737A0621	Reference Center Agreement Medacta	Orthopädie und Unfallchirurgie_739	Windhager Reinhard
FA737A2001	Fixation of the ACL using an allograft osteosynthesis system	Orthopädie und Unfallchirurgie_739	Benca Emir
FA737A2001	Fixation of the ACL using an allograft osteosynthesis system	Orthopädie und Unfallchirurgie_739	Benca Emir
FA737B0102	Biphasic, natural and laser-engraved osteochondral constructs with nasal chondrocytes for osteochondral defect regeneration	Orthopädie und Unfallchirurgie_739	Nürnberger Sylvia

FA737B0301	Early Surgical Fixation of Low-Velocity Hip Fractures in Patients with Direct Oral Anticoagulation	Orthopädie und Unfallchirurgie_739	Weihls Valerie
FA737B0301	Early Surgical Fixation of Low-Velocity Hip Fractures in Patients with Direct Oral Anticoagulation	Orthopädie und Unfallchirurgie_739	Weihls Valerie
FA608A0325	TBI	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA608A0326	TBI-2	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA608A0327	TBI-3	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA608A0328	TBI-4	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA681A0209	Understanding Granulomatous Disease in a Sarcoid Animal Model	Pathobiochemie und Genetik_306	Weichhart Thomas
FA681A0504	RTT Zellmodell 1	Pathobiochemie und Genetik_306	Steinkellner Hannes
FA681A0505	RTT Zellmodell 2	Pathobiochemie und Genetik_306	Steinkellner Hannes
FW681A0101	Targeting cellular senescence based on inter-organelle communication, multi-level proteostasis and metabolic control	Pathobiochemie und Genetik_306	Schösserer Markus

FW681A0201	Transformation of Pre-Clinics into Clinics by Organoids	Pathobiochemie und Genetik_306	Mikula Mario
FA791A1029	A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA	Pathologie_791	Kain Renate
FA791A1030	A Phase 3 Trial of Fianlimab (REGN3767, anti-LAG-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma	Pathologie_791	Kain Renate
FA791A1130	Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1152	M20-621 - A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1153	AERN - Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - An international multicenter Phase II trial	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1426	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer"	Pathologie_791	Haitel Andrea

FA791A1641	Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1642	EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestran vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1643	A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1644	ABCSG 55N/AMBER: DESCRIPTION OF PATIENTS WITH HER2 POSITIVE BREAST CANCER UNDERGOING NEOADJUVANT TREATMENT AND DEVELOPMENT OF A DYNAMIC COMPOSITE RISK SCORE TO PREDICT THE RISK OF DISTANT RECURRENCE	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1645	Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA	Pathologie_791	Bago-Horvath Zsuzsanna

FA791A1646	EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestran vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1647	ABCSG 55N/AMBHER: DESCRIPTION OF PATIENTS WITH HER2 POSITIVE BREAST CANCER UNDERGOING NEOADJUVANT TREATMENT AND DEVELOPMENT OF A DYNAMIC COMPOSITE RISK SCORE TO PREDICT THE RISK OF DISTANT RECURRENCE	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1648	A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and Early Stage HER2-Negative Breast Cancer (OlympiaN)) Protocol Number D931CC00001	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A2112	A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma	Pathologie_791	Pammer Johannes
FA791A2608	AC2101: Studying drug response in solid tumour tissue of lung cancer patients ex vivo - a pilot study	Pathologie_791	Geleff Silvana
FA791A2802	A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma" Zentrum Prof. Jäger	Pathologie_791	Schiefer Ana-Iris

FA791A3303	ABCSG 52 / ATHENE: An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEOadjuvant therapy for HER2-positive early breast cancer	Pathologie_791	Hofstetter Gerda
FA791A3306	ABCSG 52 / ATHENE: An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEOadjuvant therapy for HER2-positive early breast cancer	Pathologie_791	Hofstetter Gerda
FA791A3409	A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy	Pathologie_791	Comperat Eva Maria
FA791A3410	A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer” (VOLGA) Protocol Number D910PC00001	Pathologie_791	Comperat Eva Maria
FW791A0101	Transformation of Pre-Clinics into Clinics by Organoids	Pathologie_791	Egger Gerda

FA791A1151	An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)	Pathologie_791	Simonitsch-Klupp Ingrid
FA623A0214	A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis with Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately from a Japanese Encephalitis Vaccine	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann-Schmidt Ursula
FA623A0225	Adjuvanted allergen molecules for Treatment and prevention of allergy	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann-Schmidt Ursula
FA623A0227	A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann-Schmidt Ursula
FA623A0227	A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann-Schmidt Ursula
FA623A0511	Strengthening Genetic Biocontrol Capacities under Climate Change in Armenia	Pathophysiologie, Infektiologie und Immunologie_370	Walochnik Julia

FA624A0215	In vitro immunogenicity assays I	Pathophysiologie, Infektiologie und Immunologie_370	Steinberger Peter
FA624A0402	Viral particle-based vaccines for treatment and prevention of allergy	Pathophysiologie, Infektiologie und Immunologie_370	Pickl Winfried
FA624A0601	Projekt F0999906863 Immunzellen Analyse	Pathophysiologie, Infektiologie und Immunologie_370	Boucheron Nicole
FA624A0602	Projekt F0999906864 Immunzellen Analyse	Pathophysiologie, Infektiologie und Immunologie_370	Boucheron Nicole
FA644A0111	Neue auf Stimuli reagierende Protein-Nanokapseln zur gezielten Wirkstofffreisetzung in der Brustkrebstherapie	Pathophysiologie, Infektiologie und Immunologie_370	Stockinger Hannes
FA644A0404	The triboreactor as breakthrough remediation strategy for safeguarding human and environmental health	Pathophysiologie, Infektiologie und Immunologie_370	Sommer Regina
FA644A0510	Mikrobiologische und chemophysikalische Echtzeitparameter zur Qualitätskontrolle in der mobilen Trinkwasseraufbereitung	Pathophysiologie, Infektiologie und Immunologie_370	Kirschner Alexander
FA644A0605	Characterization of T cell engager mediated synapse	Pathophysiologie, Infektiologie und Immunologie_370	Huppa Johannes
FA644A0801	Immunometabolic analyses of transmissible cancer	Pathophysiologie, Infektiologie und Immunologie_370	Bergthaler Andreas
FA648A0111	DARC (Danube Allergy Research Cluster) - Towards Cure of Allergy, Teilprojekt #07: "From molecular structures of food allergens and food matrix components towards	Pathophysiologie, Infektiologie und Immunologie_370	Hoffmann-Sommergruber Karin

	diagnosis, treatment and prevention of food allergy."		
FA648A0311	Allergen-specific approaches targeting the nasal mucosa for treatment and prevention of allergy	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0312	Development of prophylactic allergy vaccines	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0313	Developing effective allergen-specific immunotherapy	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0316	Allergen profiling of asthma subjects within the LEAD Study	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0808	Analysis of allergen-induced degranulation of basophil cells	Pathophysiologie, Infektiologie und Immunologie_370	Breiteneder Heimo
FA648A0808	Analysis of allergen-induced degranulation of basophil cells	Pathophysiologie, Infektiologie und Immunologie_370	Breiteneder Heimo
FA648A1022	Bildanalyse_Eisen - Talente: Praktika für Schülerinnen und Schüler	Pathophysiologie, Infektiologie und Immunologie_370	Ellinger Isabella
FA648A1023	Bildanalyse_Eisen - Talente: Praktika für Schülerinnen und Schüler	Pathophysiologie, Infektiologie und Immunologie_370	Ellinger Isabella
FA648A1712	Praxisleitfäden für eine ME/CFS-orientierte Primärversorgungseinrichtung	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Eisenhuber Eva

FA648A2101	Molecular strategies for oral tolerance against house dust mite allergy	Pathophysiologie, Infektiologie und Immunologie_370	Vrtala Susanne
FA648A2302	Systems immunology in immuno-oncology	Pathophysiologie, Infektiologie und Immunologie_370	Mechtcheriakova Diana
UE64806002	Schimmelpilzallergie in Österreich	Pathophysiologie, Infektiologie und Immunologie_370	Jensen-Jarolim Erika
UE64806005	Systems biology research in immuno-oncology	Pathophysiologie, Infektiologie und Immunologie_370	Mechtcheriakova Diana
FA625A0905	Testing of novel Croma device for preparation of Platelet-rich Plasma (PRP) and comparing the levels of growth factors obtained against the current gold standard	Physiologie und Pharmakologie_350	Assinger Alice
FA625A1102	Themis - Onkologische Therapieoptionen	Physiologie und Pharmakologie_350	Schabbauer Gernot
FA625A1106	Loop Immunmodulation; LOOP LAB evaluation in small animal models	Physiologie und Pharmakologie_350	Schabbauer Gernot
FA641A0117	Aktivierung von Gs-gekoppelte EP2-Rezeptoren	Physiologie und Pharmakologie_350	Zebedin-Brandl Eva Maria
FA641A1301	A research platform for the preclinical development of future peptide drug candidates	Physiologie und Pharmakologie_350	Hellinger Roland
FA683A0201	Brain and Behavior	Physiologie und Pharmakologie_350	Pollak-Monje Quiroga Daniela

FA731F0703	RANGER®: A Multicenter Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Radtke Christine
FA731F0703	RANGER®: A Multicenter Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Radtke Christine
FA763C0121	EU H2020 Refugee Emergency: DEFining and Implementing Novel Evidence-based psychosocial interventions	Psychiatrie und Psychotherapie_763	Wancata Johannes
FA763C0802	PPIE EXPLORATION CALL: VOICE+ HOW TO TELL	Psychiatrie und Psychotherapie_763	Hinterbuchinger Barbara
UE76306002	Psychosoziale Bedürfnisse innerhalb der jüdischen Gemeinde Wien	Psychiatrie und Psychotherapie_763	Wancata Johannes
FA638A0501	EU H Biomarker und mechanistische Teilstudie (WP1+2) SHIFT2HEALTH	Public Health_380	Papantoniou Kyriaki
FA646A0304	ROADS to Health: Entscheidungsunterstützung für das Pandemiemanagement der Zukunft	Public Health_380	Kutalek Ruth
FA646A0703	Less is More: De-Prescribing Pharmaceuticals for Patient Safety and Sustainable Public Health	Public Health_380	Grabovac Igor
FA646A0704	Cancer prevention among individuals with mental ill-health: co-adapting and implementing patient navigation for primary cancer prevention	Public Health_380	Grabovac Igor

FA646A0803	EU H Interventionsstudie (WP4) SHIFT2HEALTH	Public Health_380	Winzer Eva
FA646A0902	Qualitative und quantitative Studie zum Vorkommen von Female Genital Mutilation/Cutting (FGM/C) in Österreich	Public Health_380	Jirovsky- Platter Elena
FA646A1201	ACE Casino	Public Health_380	Fischer Gabriele
FA646A1202	ASW Wetten	Public Health_380	Fischer Gabriele
FA646A1301	MigraCare - Einbindung von 24- Stunden-Betreuer:innen in Pflegetnetzwerke in Österreich	Public Health_380	Wojczewski Silvia
FA646A1401	EU H Querschnittsstudie (WP1+2) SHIFT2HEALTH	Public Health_380	Wakolbinger Maria
FA646A1501	CoMitMenT: Co-Design-Strategien mit psychisch erkrankten Menschen zur körperlichen Ge- sundheitsförderung	Public Health_380	Schiffler Tobias
FA647A0519	Flexibler NutzerInnenkomfort in viertelstündlich CO2-neutralen Plusenergiequartieren	Public Health_380	Hutter Hans- Peter
FA647A0801	New Options for Resilient Measures for human health and well-being in the construction industry under climate change in Austria	Public Health_380	Haluza Daniela
FA647A0804	Making Green Inclusive. Ecosystem Services, Health Impact Assessment and Participative Scenarios	Public Health_380	Haluza Daniela

FA669A0108	EU H2020 The I-LIVE project. Live well, die well	Public Health_380	Simon Judit
FA669A0109	Pramiprexole in refractory depression: Efficacy and mechanism (PAX-D)	Public Health_380	Simon Judit
FA669A0110	Investigation of diagnostic and treatment pathways and comorbidity profiles of prostate and colorectal cancer patients focusing on health economic aspects in AT	Public Health_380	Simon Judit
FA669A0110	Investigation of diagnostic and treatment pathways and comorbidity profiles of prostate and colorectal cancer patients focusing on health economic aspects in AT	Public Health_380	Simon Judit
FA669A0112	Establishing a Reference Unit Cost catalogue for the optimized evaluation and planning of mental healthcare in Vienna	Public Health_380	Simon Judit
UE63806001	Kooperation KfH - Abteilung für Epidemiologie	Public Health_380	Schernhammer Eva
FA771B0828	A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B0863	A Phase IB/II open-Label, multicenter, randomized controlled study investigating the safety, tolerability, pharmacokinetics, and efficacy of mesunetuzumab (BTCT4465A) in combination with chop or chppolatunumab vedotin in patients with b-cell non-hodgkin lymphoma	Radiologie und Nuklearmedizin_771	Herold Christian

FA771B0889	A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B0890	I8F-MC-GPIG: Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (Treasure-CKD)	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B0891	A Phase 3 Study of the Heparin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera, protocol no. PTG-300-11, (Study) on the compound PTG-300 (Study Drug)	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B1306	Strengthening the screening of Lung Cancer in Europe	Radiologie und Nuklearmedizin_771	Prosch Helmut
FA771B1307	1305-0014 und 1305-0023 Eine doppelblinde, randomisierte, placebokontrollierte Studie zur Untersuchung der Wirksamkeit und Sicherheit von BI 1015550 über einen Zeitraum von mindestens 52 Wochen bei Patienten mit idiopathischer Lungenfibrose (Idiopathic Pulmonary Fibrosis, IPF).	Radiologie und Nuklearmedizin_771	Prosch Helmut

FA771B1308	Content-Based Retrieval System	Radiologie und Nuklearmedizin_771	Prosch Helmut
FA771B1604	Improvement and protection of women's health at a population level by Value Based Breast Screening in Vienna	Radiologie und Nuklearmedizin_771	Baltzer Pascal
FA771D0529	"A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)" (MK7684A-010, Site number 0600)	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771D0903	Randomisierte, placebo-kontrollierte klinische Prüfung der Wirksamkeit d myokardialen Schutzes bei Pax. mit postakuter entzündlicher Herzbeteiligung infolge CCOVID-19	Radiologie und Nuklearmedizin_771	Beitzke Dietrich
FA771D1401	Trustworthy AI Tools for the Prediction of Obesity Related Vascular Diseases	Radiologie und Nuklearmedizin_771	Langs Georg
FA771E0215	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease	Radiologie und Nuklearmedizin_771	Kainberger Franz
FA771E0509	European Federation for Cancer Images	Radiologie und Nuklearmedizin_771	Langs Georg
FA771E1202	ENLIGHTEN I: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults	Radiologie und Nuklearmedizin_771	Schwarz-Nemec Ursula

FA771E1401	Validation of MR ChondralHealth-derived morphometric analysis and GLCM texture analysis using cadaver knees	Radiologie und Nuklearmedizin_771	Juras Vladimir
FA771E1601	“A MULTICENTER, SINGLE-ARM, OPEN-LABEL, EXTENSION, ROLLOVER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS”	Radiologie und Nuklearmedizin_771	Kasprian Gregor
FA771E1701	Spinal Cord Imaging	Radiologie und Nuklearmedizin_771	Robinson Simon
FA771E1801	A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy	Radiologie und Nuklearmedizin_771	Schmook Maria
FA771G0238	Amendment to CBmed Consortium Agreement 2015-2018 (FP1)	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0271	Labeling - Evaluation - Model Systems	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0272	A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)”	Radiologie und Nuklearmedizin_771	Hacker Marcus

FA771G0273	Preclinical molar ratio study to mitigate [90Y]Y-PentixaTher-mediated myelosuppression.	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0274	Investigating Mechanisms and Models Predictive of Accesability of Therapeutics into the Brain	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA774A0906	Characterization of dependencies of relative biological effectiveness (RBE) of carbon ion radiation therapy (CIRT) in comparison to proton therapy, in human pancreatic cancer cell lines and normal gastrointestinal tissues	Radioonkologie_774	Georg Dietmar
FA774A1202	A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma	Radioonkologie_774	Herrmann Harald
UE77406004	Characterization of dependencies of relative biological effectiveness (RBE) of carbon ion radiation therapy (CIRT) in comparison to proton therapy, in human pancreatic cancer cell lines and normal gastrointestinal tissues	Radioonkologie_774	Georg Dietmar
FA731T0601	The molecular biological signalling of the trepostinil's anti-fibrotic action in idiopathic pulmonary fibrosis	Thoraxchirurgie_733	Aigner Clemens
FA733A0101	Characterisation of the Survival Benefit of Pre-Treatment with Nintedanib on Lung Transplant Survival in Patients with IPF	Thoraxchirurgie_733	Aigner Clemens
FA733A0201	Evaluating the addition of hemodiafiltration to ex-vivo lung perfusion – impact on the regeneration of marginal donor lungs: a prospective randomised pilot trial	Thoraxchirurgie_733	Benazzo Alberto

FA733A0302	International documentation on the use of Cytotect CP Biotest for patients after lung and heart transplantation	Thoraxchirurgie_733	Jaksch Peter
FA733A0401	AC2101: Studying drug response in solid tumour tissue of lung cancer patients ex vivo- a pilot study	Thoraxchirurgie_733	Hoda Mir Ali Reza
FA727A0618	A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	Transfusionsmedizin und Zelltherapie_727	Worel Nina
FA727A0619	An open-label, multi-center, dose-escalation Phase Ib study to determine the recommended phase 2 dose of APN401 in patients with advanced solid tumors	Transfusionsmedizin und Zelltherapie_727	Worel Nina
FA727A0620	Herstellung APN401 für die APN401-104 Studie	Transfusionsmedizin und Zelltherapie_727	Worel Nina
FA670A0107	Surefil one als Amalgamersatz für Klasse II Füllungen im Studentenkurs	Universitätszahnklinik_670	Schedle Andreas
FA743A0220	Eine multinationale, randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zur Wirksamkeit und Sicherheit von ODM-201 bei männlichen Hochrisikopatienten mit nicht metastasiertem, kastrationsresistentem Prostatakrebs	Urologie_743	Shariat Shahrokh

FA743A0224	Offene, einarmige, multizentrische Sicherheitsstudie zu Atezolizumab bei lokal fortgeschrittenem oder metastasierendem urothelialen oder nicht urothelialen Harnwegkarzinom	Urologie_743	Shariat Shahrokh
FA743A0229	Eine internationale, multizentrische Phase Ib/II Studie mit Rogaratinib in Kombination mit Atezolizumab als Erstlinientherapie bei Patienten mit FGFR-positivem lokal fortgeschrittenem oder metastasiertem Urothelkarzinom, die für eine cisplatinhaltige Chemotherapie nicht geeignet sind	Urologie_743	Shariat Shahrokh
FA743A0230	Beurteilung des Xpert Blasenkrebsmonitor-Tests im Vergleich zur Zystoskopie für die Nachbeobachtung von Patienten mit Vorgeschichte von geringem bis mittlerem Risiko eines nicht-muskelinvasiven Blasenkrebses (NMIBC): eine prospektive internationale multizentrische Beobachtungsstudie	Urologie_743	Shariat Shahrokh
FA743A0237	Eine Phase-III-Studie zu Erdafitinib im Vergleich mit Vinflunin oder Docetaxel oder Pembrolizumab bei Patienten mit fortgeschrittenem Urothelkarzinom und ausgewählten FGFR-Gen-Aberrationen	Urologie_743	Shariat Shahrokh
FA743A0239	A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of a PSMA bispecific T-cell Engager (BiTE) AMG 160 in Subjects with Metastatic Castration Resistant Prostate Cancer (mCRPC)	Urologie_743	Shariat Shahrokh
FA743A0240	Characterization of the PARP Inhibitor Talazoparib as Novel Therapeutic Option in Advanced Bladder Cancer	Urologie_743	Shariat Shahrokh
FA743A0245	Einarmige Open-Label-Studie der Phase 2 mit monoklonalem Anti-PD1 MK-3475-Antikörper (Pembrolizumab) bei Patienten mit muskelinvasivem rothelkarzinom vor radikaler Zystektomie	Urologie_743	Shariat Shahrokh

FA743A0250	A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY	Urologie_743	Shariat Shahrokh
FA743A0250	A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY	Urologie_743	Shariat Shahrokh
FA743A0251	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR)	Urologie_743	Shariat Shahrokh
FA743A0252	A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors	Urologie_743	Shariat Shahrokh
FA743A0253	A Phase II, Multicentre, Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Clear-Cell Variant Renal Cell Carcinoma Who Progressed After 1st Line Treatment with Checkpoint Inhibitors	Urologie_743	Shariat Shahrokh

FA743A0254	A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma	Urologie_743	Shariat Shahrokh
FA743A0255	A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy	Urologie_743	Shariat Shahrokh
FA743A0256	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	Urologie_743	Shariat Shahrokh
FA743A0257	A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma after previous therapy with checkpoint inhibitor Treatment.	Urologie_743	Shariat Shahrokh
FA743A0259	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy” (MK-6482-011-Site number 1021)	Urologie_743	Shariat Shahrokh
FA743A0263	A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA®) VERSUS SUNITINIB (SUTENT®) MONOTHERAPY IN THE	Urologie_743	Shariat Shahrokh

	FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA		
FA743A0265	Eine einarmige klinische Prüfung (Phase II) zur Untersuchung eines abgestuften immuntherapeutischen Ansatzes in Patienten mit fortgeschrittenem oder metastasiertem Nierenzellkarzinom	Urologie_743	Shariat Shahrokh
FA743A0268	A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence.	Urologie_743	Shariat Shahrokh
FA743A0269	Eine randomisierte, offene, multizentrische Phase-III-Studie zur Bestimmung der Wirksamkeit und Sicherheit von Durvalumab in Kombination mit Tremelimumab und Enfortumab Vedotin oder Durvalumab in Kombination mit Enfortumab Vedotin zur perioperativen Behandlung bei Patienten, die nicht für Cisplatin geeignet sind und sich einer radikalen Zystektomie wegen muskelinvasivem Blasenkrebs unterziehen	Urologie_743	Shariat Shahrokh
FA690A0602	Induction of HBV Virus neutralizing antibodies in healthy vaccine naive adults and non-responders and in patients chronically infected with HBV Using VVX001	Virologie_307	Aberle Judith
FA690A0704	Überwachung der Respiratorischen Rynzytial Viren in Österreich durch das Diagnostische Influenza Netzwerk Österreich	Virologie_307	Redlberger-Fritz Monika

43. Stück Mitteilungsblatt, Studienjahr 2022/2023,
ausgegeben am 22.08.2023, Nr. 56

71

Markus Müller
Rektor